Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H21FN6O |
Molecular Weight | 320.3652 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
F[C@H]1C[C@@H](C#N)N(C1)C(=O)CN[C@@H]2CC[C@H](CN3C=NC=N3)C2
InChI
InChIKey=JSYGLDMGERSRPC-FQUUOJAGSA-N
InChI=1S/C15H21FN6O/c16-12-4-14(5-17)22(8-12)15(23)6-19-13-2-1-11(3-13)7-21-10-18-9-20-21/h9-14,19H,1-4,6-8H2/t11-,12-,13+,14-/m0/s1
Molecular Formula | C15H21FN6O |
Molecular Weight | 320.3652 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Melogliptin (EMD 675992 or GRC 8200) is an orally bioavailable dipeptidyl peptidase IV (DPP IV) inhibitor. Melogliptin was undergoing phase II clinical trials at Glenmark Pharmaceuticals and Merck KGaA for the treatment of type 2 diabetes. The completed 12 week Phase IIb clinical trial in 494 patients with type 2 diabetes melogliptin improved glycemic control in patients with type 2 diabetes mellitus and exhibited excellent safety and tolerability profile.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) Sources: https://newdrugapprovals.org/2015/12/11/melogliptin/ |
1.61 nM [IC50] |
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:23:24 GMT 2023
by
admin
on
Sat Dec 16 16:23:24 GMT 2023
|
Record UNII |
I3N8016NKU
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C98086
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID701007159
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
PRIMARY | |||
|
300000036967
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
PRIMARY | |||
|
I3N8016NKU
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
PRIMARY | |||
|
C87620
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
PRIMARY | |||
|
8905
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
PRIMARY | |||
|
11623906
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
PRIMARY | |||
|
868771-57-7
Created by
admin on Sat Dec 16 16:23:25 GMT 2023 , Edited by admin on Sat Dec 16 16:23:25 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|